Investing.com - Guggenheim raised its price target on Maze Therapeutics (NASDAQ:MAZE) to $46.00 from $34.00 on Friday, while maintaining a Buy rating on the stock. The new target represents ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback